Table of Contents:
Chapter 1. Research Methodology and Scope
- Market Segmentation and Scope
- Regional Coverage
- Objectives
- Research Methodology
Chapter 2. Executive Summary
- Market Landscape
- Market Size & Forecast
- Competitive Landscape
Chapter 3. Ganirelix Acetate Market: By Dosage Form Market Trends, Size, and Future Outlook
- By Dosage Form Market Size (US$), CAGR (%), and Forecast (2023-2031)
- By Dosage Form Definitions, Technology Landscape
- By Dosage Form Market Drivers
- Rising demand for convenient self-administered formulations
- High growth in injectable segment
- By Dosage Form Market Restraints
- Limitations related to parenteral mode of administration
Chapter 4. Ganirelix Acetate Market: By Distribution Channel Market Trends, Size, and Future Outlook
- By Distribution Channel Market Size (US$), CAGR (%), and Forecast (2023-2031)
- By Distribution Channel Definitions, Technology Landscape
- By Distribution Channel Market Drivers
- High usage in hospital pharmacies owing to supervised administration
- Increasing online sales driven by discounts and convenience
- By Distribution Channel Market Restraints
- Low availability in retail pharmacies and clinics
Chapter 5. Ganirelix Acetate Market: Regional Market Trends, Size, and Future Outlook
- Regional Market Size (US$), CAGR (%), and Forecast (2023-2031)
- Regional Definitions, Technology Landscape
- Regional Market Drivers
- High ART adoption and favorable reimbursement in North America
- Rising medical tourism for IVF in Asia Pacific
- Regional Market Restraints
- Stringent regulations restricting IVF in Latin America
Chapter 6. Ganirelix Acetate Market: Competitive Landscape
- Merck & Co.
- Ferring Pharmaceuticals
- Sun Pharmaceutical
- Cook Medical
- Vetter Pharma-Fertigung
- Monash IVF
- ChemProcess Pvt. Ltd.
- Ansh Labs
- CMC Biologics
- Teva (Actavis)
Chapter 7. Research Methodology
- Primary Research
- Secondary Research
- Assumptions
- IDataAcumen Analysis
- Paid Databases
Chapter 8. Appendix
- About Us
Frequently Asked Questions
The Ganirelix Acetate Market is estimated to be USD 423 million in 2024.
Increasing infertility rates, growth of IVF procedures, new product launches, government funding for ART, andmedical tourism for fertility treatments.
High treatment costs, low awareness levels, side effects, and stringent regulatory policies for drug approvals.
The injectable dosage form segment dominates the Ganirelix Acetate Market with over 90% share.
Merck & Co., Ferring Pharmaceuticals, Sun Pharmaceuticals, Cook Medical, Vetter Pharma-Fertigung, and Monash IVF.
The global market is expected to reach USD 615.3 million by 2031 growing at a CAGR of 5.5% during 2024-2031.
Rising infertility rates, increase in IVF procedures, growth in fertility tourism, favorable reimbursement policies, product launches and mergers and acquisitions.